Method for inhibiting inflammatory responses

• US 6,638,518 B1
• Filed: 02/22/2000
• Issued: 10/28/2003
• Est. Priority Date: 02/22/1999
• Status: Expired due to Term

• Current Assignee: University of Iowa Research Foundation
• Original Assignee: University of Iowa Research Foundation
• Inventors: Kline, Joel N., Ratliff, Timothy L.
• Primary Examiner(s): DUFFY, PATRICIA ANN
• Application Number:
  US09/510,031
• Time in Patent Office: 1,344 Days
• Field of Search: 424/184.1, 424/185.1, 424/190.1, 424/234.1, 424/248.1, 424/278.1, 424/282.1, 424/192.1, 530/300, 530/350
• US Class Current: 424/282.1
• CPC Class Codes: A61K 38/164 from bacteria
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07K 14/35 from Mycobacteriaceae (F)

Abstract

The present invention provides methods for treating at least one symptom of an inflammatory response in a mammal by administering a polypeptide to the mammal. The polypeptide can be a microbial polypeptide, or a Mycobacterial polypeptide. The present invention further provides an inflammation reaction inhibiting composition that includes a microbial polypeptide and a pharmaceutically acceptable carrier.

Claims

1. A method for treating at least one symptom of an inflammatory response in a mammal comprising:

administering an effective amount of an isolated microbial polypeptide to the mammal such that at least one symptom of the inflammatory response is inhibited, wherein the microbial polypeptide comprises an amino acid sequence of SEQ ID NO;

2, and wherein the at least one symptom is associated with asthma.

7. The method of claim 1 wherein the microbial polypeptide decreases lung eosinophila in the mammal.

8. The method of claim 1 wherein the microbial polypeptide decreases airway hyperactivity in the mammal.

2. A method for treating at least one symptom of an inflammatory response in a mammal comprising administering to the mammal an isolated polypeptide such that at least one symptom of the inflammatory response is inhibited, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:

3 and amino acids 47 to 325 of SEQ ID NO;

2, wherein the carboxy terminal amino acid of SEQ ID NO;

3 is fused to the amino terminal amino acid of amino acids 47 to 325 of SEQ ID NO;

2, and wherein the at least one symptom is associated with asthma.

9. The method of claim 2 wherein the polypeptide decreases lung eosinophila in the mammal.

10. The method of claim 2 wherein the polypeptide decreases airway hyperactivity in the mammal.

3. A method for treating at least one symptom of an inflammatory response in a mammal comprising:

administering an effective amount of an isolated microbial polypeptide to the mammal such that at least one symptom of the inflammatory response is inhibited, wherein the microbial polypeptide comprises amino acids 121 to 283 of SEQ ID NO;

2, and wherein the at least one symptom is associated with asthma.

4. The method of claim 3 wherein the amino acid sequence of the microbial polypeptide comprises amino acids 112 to 283 of SEQ ID NO:

2.

5. The method of claim 3 wherein the amino acid sequence of the microbial polypeptide comprises amino acids 47 to 325 of SEQ ID NO:

2.

6. The method of claim 3 wherein the microbial polypeptide comprises an amino acid sequence of SEQ ID NO:

3 and amino acids 47 to 325 of SEQ ID NO;

2, wherein the carboxy terminal amino acid of SEQ ID NO;

3 is fused to the amino terminal amino acid of amino acids 47 to 325 of SEQ ID NO;

2.

11. The method of claim 3 wherein the microbial polypeptide decreases lung eosinophila in the mammal.

12. The method of claim 3 wherein the microbial polypeptide decreases airway hyperactivity in the mammal.